Markets have high expectations of the Swiss giant
20/03/23 -"Supported by Novartis’ ongoing profitability improvements and healthy growth potential for the firm’s marketed as well as the pipeline drugs (oncology comprised c.47% of pipeline as of end-2022), ..."
Pages
71
Language
English
Published on
20/03/23
You may also be interested by these reports :
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...
23/04/24
The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the ...
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...